Zenas BioPharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Zenas BioPharma (ZBIO) with a Buy rating and $30 price target The company’s lead autoimmune therapy, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc gamma receptor IIb, FcgammaRIIb, broadly present on B cell lineage, the analyst tells investors in a research note. The firm believes obexelimab represents an autoimmune franchise molecule with the potential for B cell therapeutic differentiation.